Laura Gaetano1, Dieter A Häring1, Ernst-Wilhelm Radue1, Nicole Mueller-Lenke1, Avinash Thakur1, Davorka Tomic1, Ludwig Kappos1, Till Sprenger2. 1. From the Medical Image Analysis Centre (L.G., E.-W.R., N.M.-L., T.S.), University Hospital Basel; Neurologic Clinic and Policlinic (L.G., L.K., T.S.), Departments of Medicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital and University of Basel; Novartis Pharma AG (D.A.H., D.T.), Basel, Switzerland; Novartis Healthcare Pvt Ltd (A.T.), Hyderabad, India; and Department of Neurology (T.S.), DKD HELIOS Klinik Wiesbaden, Germany. 2. From the Medical Image Analysis Centre (L.G., E.-W.R., N.M.-L., T.S.), University Hospital Basel; Neurologic Clinic and Policlinic (L.G., L.K., T.S.), Departments of Medicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital and University of Basel; Novartis Pharma AG (D.A.H., D.T.), Basel, Switzerland; Novartis Healthcare Pvt Ltd (A.T.), Hyderabad, India; and Department of Neurology (T.S.), DKD HELIOS Klinik Wiesbaden, Germany. till.sprenger@helios-gesundheit.de.
Abstract
OBJECTIVE: To study the effect of fingolimod on deep gray matter (dGM), thalamus, cortical GM (cGM), white matter (WM), and ventricular volume (VV) in patients with relapsing-remitting multiple sclerosis (RRMS). METHODS: Data were pooled from 2 phase III studies. A total of 2,064 of 2,355 (88%) contributed to the analysis: fingolimod 0.5 mg n = 783, fingolimod 1.25 mg n = 799, or placebo n = 773. Percentage change from baseline in dGM and thalamic volumes was evaluated with FMRIB's Integrated Registration & Segmentation Tool; WM, cGM, and VV were evaluated with structural image evaluation using normalization of atrophy cross-sectional version (SIENAX) at months 12 and 24. RESULTS: At baseline, compound brain volume (brain volume in the z block [BVz] = cGM + dGM + WM) correlated with SIENAX-normalized brain volume (r = 0.938, p < 0.001); percentage change from baseline in BVz over 2 years correlated with structural image evaluation using normalization of atrophy percentage brain volume change (r = 0.713, p < 0.001). For placebo, volume reductions were most pronounced in cGM, and relative changes from baseline were strongest in dGM. Over 24 months, there were significant reductions with fingolimod vs placebo for dGM (0.5 mg -14.5%, p = 0.017; 1.25 mg -26.6%, p < 0.01) and thalamus (0.5 mg -26.1%, p = 0.006; 1.25 mg -49.7%, p < 0.001). Reduction of cGM volume loss was not significant. Significantly less WM loss and VV enlargement were seen with fingolimod vs placebo (all p < 0.001). A high T2 lesion volume at baseline predicted on-study cGM, dGM, and thalamic volume loss (p < 0.0001) but not WM loss. Patients taking placebo with high dGM (hazard ratio [HR] 0.54, p = 0.0323) or thalamic (HR 0.58, p = 0.0663) volume at baseline were less likely to show future disability worsening. CONCLUSIONS:Fingolimod significantly reduced dGM volume loss (including thalamus) vs placebo in patients with RRMS. Reducing dGM and thalamic volume loss might improve long-term outcome.
RCT Entities:
OBJECTIVE: To study the effect of fingolimod on deep gray matter (dGM), thalamus, cortical GM (cGM), white matter (WM), and ventricular volume (VV) in patients with relapsing-remitting multiple sclerosis (RRMS). METHODS: Data were pooled from 2 phase III studies. A total of 2,064 of 2,355 (88%) contributed to the analysis: fingolimod 0.5 mg n = 783, fingolimod 1.25 mg n = 799, or placebo n = 773. Percentage change from baseline in dGM and thalamic volumes was evaluated with FMRIB's Integrated Registration & Segmentation Tool; WM, cGM, and VV were evaluated with structural image evaluation using normalization of atrophy cross-sectional version (SIENAX) at months 12 and 24. RESULTS: At baseline, compound brain volume (brain volume in the z block [BVz] = cGM + dGM + WM) correlated with SIENAX-normalized brain volume (r = 0.938, p < 0.001); percentage change from baseline in BVz over 2 years correlated with structural image evaluation using normalization of atrophy percentage brain volume change (r = 0.713, p < 0.001). For placebo, volume reductions were most pronounced in cGM, and relative changes from baseline were strongest in dGM. Over 24 months, there were significant reductions with fingolimod vs placebo for dGM (0.5 mg -14.5%, p = 0.017; 1.25 mg -26.6%, p < 0.01) and thalamus (0.5 mg -26.1%, p = 0.006; 1.25 mg -49.7%, p < 0.001). Reduction of cGM volume loss was not significant. Significantly less WM loss and VV enlargement were seen with fingolimod vs placebo (all p < 0.001). A high T2 lesion volume at baseline predicted on-study cGM, dGM, and thalamic volume loss (p < 0.0001) but not WM loss. Patients taking placebo with high dGM (hazard ratio [HR] 0.54, p = 0.0323) or thalamic (HR 0.58, p = 0.0663) volume at baseline were less likely to show future disability worsening. CONCLUSIONS:Fingolimod significantly reduced dGM volume loss (including thalamus) vs placebo in patients with RRMS. Reducing dGM and thalamic volume loss might improve long-term outcome.
Authors: Hao Jiang; Sumit Joshi; Hui Liu; Syahir Mansor; Lin Qiu; Haiyang Zhao; Timothy Whitehead; Robert J Gropler; Gregory F Wu; Anne H Cross; Tammie L S Benzinger; Kooresh I Shoghi; Joel S Perlmutter; Zhude Tu Journal: ACS Chem Neurosci Date: 2021-09-13 Impact factor: 5.780
Authors: Stefano Magon; Charidimos Tsagkas; Laura Gaetano; Raihaan Patel; Yvonne Naegelin; Michael Amann; Katrin Parmar; Athina Papadopoulou; Jens Wuerfel; Christoph Stippich; Ludwig Kappos; M Mallar Chakravarty; Till Sprenger Journal: J Neurol Date: 2020-02-10 Impact factor: 4.849
Authors: Laura Gaetano; Baldur Magnusson; Petya Kindalova; Davorka Tomic; Diego Silva; Anna Altermatt; Stefano Magon; Nicole Müller-Lenke; Ernst-Wilhelm Radue; David Leppert; Ludwig Kappos; Jens Wuerfel; Dieter A Häring; Till Sprenger Journal: Mult Scler J Exp Transl Clin Date: 2020-02-18
Authors: Tomas Uher; Jan Krasensky; Charles Malpas; Niels Bergsland; Michael G Dwyer; Eva Kubala Havrdova; Manuela Vaneckova; Dana Horakova; Robert Zivadinov; Tomas Kalincik Journal: Neurol Neuroimmunol Neuroinflamm Date: 2021-03-16
Authors: Ingrid Anne Lie; Emma Kerklingh; Kristin Wesnes; David R van Nederpelt; Iman Brouwer; Øivind Torkildsen; Kjell-Morten Myhr; Frederik Barkhof; Lars Bø; Hugo Vrenken Journal: Eur Radiol Date: 2022-01-03 Impact factor: 7.034